Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema

Chakraborty, D. P.; Mondal, Soumen; Parachuri, Nikulaa; Kumar, Nilesh; Sharma, Ashish

doi:10.1038/s41433-021-01816-3

Cited by 7 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group published data on use of BRZ in wet AMD and recalcitrant DME in Indian eyes where we did not find any inflammation with the use of BRZ [21][22][23]. Recently, Novartis terminated the RAPTOR for branch RVO and RAVEN for CRVO trials in which BRZ was dosed at 4-weekly interval due to high incidence of IOI in both groups, in the interest of patient safety [24].…”

Section: Discussionmentioning

confidence: 98%

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Chakraborty¹,

Mondal²,

Boral³

et al. 2022

Case Rep Ophthalmol

Self Cite

View full text Add to dashboard Cite

This was a single center, prospective uncontrolled nonrandomized case series. Two eyes with recalcitrant ME secondary to CRVO, who have received a minimum of ten intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, underwent IVI brolucizumab (BRZ). Patients underwent best corrected visual acuity (BCVA) testing, ophthalmic examination, and optical coherence tomography at baseline and follow-up visits (weeks 4, 8, 12, and 16). Both patients demonstrated notable improvement in BCVA and reduction of fluid on SD-OCT lasting up to week 12. At week 16, though both the eyes maintained the visual acuity gains, early increase in fluid was noted in both cases, for which second dose of IVI BRZ was given. No ocular or systemic adverse events were noted in these 2 cases.

show abstract

Section: Discussionmentioning

confidence: 98%

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Chakraborty¹,

Mondal²,

Boral³

et al. 2022

Case Rep Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors postulate this contralateral effect may be due to systemic escape of the molecule or due to the disease’s natural progression. A retrospective interventional single-center study was conducted by Chakraborty et al [ 30 ] in 13 eyes of 13 patients with chronic, non-responsive, center-involved DME. Eyes had previously been treated with IVI of anti-VEGF alone or in combination with IV corticosteroids.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experience With Brolucizumab 6 mg for Diabetic Macular Edema

Bragança,

Ferreira,

Leite

et al. 2024

Cureus

View full text Add to dashboard Cite

Background This study aimed to assess functional and anatomical outcomes after one month of treatment with a single intravitreal injection (IVI) of brolucizumab in patients with diabetic macular edema (DME). Methodology A retrospective study was conducted on eyes with DME who received a single IVI of brolucizumab. The study was designed to assess visual function and optical coherence tomography (OCT) biomarkers at baseline and one month following a single brolucizumab IVI. A sub-analysis was conducted between the following two groups: group 1 - treatment with brolucizumab due to burden, needle phobia, or non-compliance (responders to standard anti-vascular endothelial growth factor (VEGF) or naïve); and group 2 - non-responsive to previous therapies (standard anti-VEGF ± corticosteroids). The main outcome measures included best-corrected visual acuity (BCVA; Early Treatment of Diabetic Retinopathy Study (ETDRS) letters), central foveal thickness, and OCT biomarkers such as the presence of subretinal fluid, the number of hyperreflective dots, the disorganization of retinal inner layers, the disruption of outer plexiform layer, external limiting membrane and ellipsoid zone, the presence of cysts in the nuclear layers (outer (ONL) and inner (INL)), and the number of cysts in ONL versus those in the INL. Safety outcomes were assessed. Results A total of 59 eyes from 42 patients were included, of which 47 eyes were in group 1 and 12 eyes were in group 2. At one month, patients had an improvement of two ETDRS letters on BCVA (p = 0.020), lower central foveal thickness (p < 0.001), fewer hyperreflective dots (p = 0.016), less outer plexiform layer disruption (p = 0.004), less inner and outer nuclear layer cysts (p < 0.001 and p = 0.001, respectively) and better relationship between ONL and INL cysts (p = 0.022). Results were significant in the subgroup of patients with previous responsive DME. No adverse events were reported. Conclusions This study demonstrates the effectiveness and safety after one injection of brolucizumab 6 mg in the management of DME, especially in previously responsive DME patients.

show abstract

“…In addition, more than 90% of the patients extended their treatment interval between 12 and 16 weeks. 74 …”

Section: Real-world Clinical Datamentioning

confidence: 99%

“… No AEs were noted. Chakraborty et al 74 2021 Retrospective, consecutive, interventional, uncontrolled, single-centre 13 (13) 1. BCVA improved significantly from 0.53 ± 0.08 log MAR at baseline to 0.40 ± 0.12 (p=0075) after the first IVI.…”

Section: Real-world Clinical Datamentioning

confidence: 99%

“…In addition, more than 90% of the patients extended their treatment interval between 12 and 16 weeks. 74 Chakraborty et al were the first to report a case of contralateral response following intravitreal administration of brolucizumab in one eye of a patient with newly diagnosed bilateral DMO. 75 Bilateral visual gain with a reduction in macular thickness were revealed at one-month follow-up visit that were most probably associated with the phenomenon of systemic escape.…”

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies

Karasavvidou¹,

Tranos²,

Panos³

2022

DDDT

View full text Add to dashboard Cite

Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.

show abstract

Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema

Cited by 7 publications

References 7 publications

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series

Real-World Experience With Brolucizumab 6 mg for Diabetic Macular Edema

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies

Contact Info

Product

Resources

About